By Finance Pulse in Pfizer —

Sangamo Stock Drops 67% After Pfizer Partnership Ends

Sangamo Therapeutics' shares nosedived by 67% following Pfizer's decision to terminate their hemophilia A gene therapy collaboration. Explore the impact on biotech stocks.

A dramatic stock market graph with a downward trend, set against a backdrop of scientific imagery to
Sangamo Stock Drops 67% After Pfizer Partnership Ends

Sangamo stock plunged 67% after Pfizer ended their hemophilia A gene therapy partnership.

Source